- Home
- SW vs BIIB Comparison
SW vs BIIB Comparison
Compare SW & BIIB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | SW | BIIB |
|---|---|---|
| Founded | 1934 | 1978 |
| Country | Ireland | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 20.2B | 24.2B |
| IPO Year | N/A | 1991 |
Fundamental Metrics
Financial Performance| Metric | SW | BIIB |
|---|---|---|
| Price | $39.99 | $183.66 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 11 | 22 |
| Target Price | $52.00 | ★ $177.40 |
| AVG Volume (30 Days) | ★ 4.6M | 2.3M |
| Earning Date | 02-11-2026 | 02-11-2026 |
| Dividend Yield | ★ 4.21% | N/A |
| EPS Growth | ★ 109.82 | N/A |
| EPS | 1.42 | ★ 10.97 |
| Revenue | ★ $31,138,000,000.00 | $10,065,900,000.00 |
| Revenue This Year | $52.96 | $3.58 |
| Revenue Next Year | $2.73 | N/A |
| P/E Ratio | $28.83 | ★ $16.64 |
| Revenue Growth | ★ 89.50 | 4.77 |
| 52 Week Low | $32.73 | $110.04 |
| 52 Week High | $56.05 | $185.17 |
Technical Indicators
Market Signals| Indicator | SW | BIIB |
|---|---|---|
| Relative Strength Index (RSI) | 61.45 | 66.88 |
| Support Level | $38.52 | $171.61 |
| Resistance Level | $38.92 | $178.46 |
| Average True Range (ATR) | 0.89 | 4.09 |
| MACD | 0.23 | 0.33 |
| Stochastic Oscillator | 61.43 | 90.32 |
Price Performance
Historical ComparisonAbout SW Smurfit WestRock plc Ordinary Shares
Smurfit WestRock manufactures corrugated packaging and consumer packaging, such as folding cartons and paperboard. After the merger of Smurfit Kappa and WestRock in summer 2024, Smurfit WestRock became the largest producer of containerboard in the world, with substantial operations in North America, South America, and Europe.
About BIIB Biogen Inc.
Biogen is an established biopharmaceutical company focused on treatments for neurological diseases and rare diseases. Its declining multiple sclerosis franchise is its largest revenue generator and contributed 45% of total revenue in 2024. Biogen also generates significant revenue from its CD20 collaboration agreements with Roche (18% of total in 2024), which includes oncology drugs Rituxan and Gazyva and multiple sclerosis drug Ocrevus. Biogen's newer franchises include Spinraza (spinal muscular atrophy, with partner Ionis), Leqembi (Alzheimer's disease, collabroation revenue from its partner Eisai), Skyclarys (Friedreich's ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (amyotrophic lateral sclerosis, Ionis).